You've heard these three names thrown around in the same breath, like picking between them is a style choice. It's not. All three activate the GLP-1 receptor, the switch behind appetite reduction and blood sugar control. That's where the family resemblance ends. Each one bolts on a receptor the last one didn't have, and the research suggests those additions genuinely change what happens in your body, not just the marketing copy.
Semaglutide, the original
Semaglutide (Ozempic for diabetes, Wegovy for weight loss) works one receptor, GLP-1, the gut hormone that tells your pancreas to release insulin, slows digestion, and tells your brain you've had enough. Semaglutide is just a lab-made stand-in for a signal your body already sends.
It's also the one with the longest track record by a wide margin. Years of large trial data back both its metabolic and cardiovascular effects, and it's the most widely available of the three, with insurance coverage the newer compounds mostly don't have yet.
In trials, semaglutide produced average weight loss of around 15% of body weight, a number that made headlines when it first published.
Tirzepatide, the one that stacks a second receptor
Tirzepatide (Mounjaro, Zepbound) hits two receptors, GLP-1 and GIP, a second gut hormone with its own role in insulin release and fat metabolism. Activating both at once appears to add up rather than just repeat the same signal twice.
In head-to-head trials against semaglutide, tirzepatide consistently came out ahead: around 20 to 22% average weight loss at higher doses versus 15% for semaglutide. That's not a rounding difference.
The leading theory is that hitting fat metabolism through two pathways at once beats hitting it through one. Whether that edge holds up for outcomes beyond the scale, cardiovascular events, long-term metabolic disease, is still being worked out.
Retatrutide, the one still proving itself
Retatrutide adds a third receptor, glucagon. Glucagon usually gets cast as the hormone that raises blood sugar, the opposite job of insulin, but it also drives fat breakdown and metabolic rate. Add glucagon receptor activity to GLP-1 and GIP, and early data suggests you get fat loss the two-receptor compounds don't fully reach.
The early numbers are hard to ignore. Some trial participants lost more than 24% of body weight, the highest average this class has produced so far. But "early" is doing real work in that sentence. As of mid-2026, retatrutide is still in clinical trials with no FDA approval, which means it's available only as a research compound, not something a prescriber can write you a script for.
The triple mechanism also opens questions nobody's fully answered. At higher doses, glucagon receptor activation has shown up alongside muscle loss in some trial data, and researchers are still working through what that means. The side effect profile at real-world doses isn't settled science yet. Impressive early results and proven safety are two different things, and only one of them is true here.
How they stack up
| Compound | Receptors Targeted | Avg. Weight Loss (trials) | Approval Status |
|---|---|---|---|
| Semaglutide | GLP-1 | ~15% | FDA approved |
| Tirzepatide | GLP-1 + GIP | ~20–22% | FDA approved |
| Retatrutide | GLP-1 + GIP + Glucagon | ~24%+ | In trials (as of mid-2026) |
What actually matters when you're the one deciding
The mechanism story is real, and the trial pattern is consistent. More receptors has meant more average weight loss, so far. But averages flatten a lot of individual variation. Some women respond strongly to semaglutide alone and never need to think about the other two. Others don't respond the way the trial averages promised, or tolerate tirzepatide better than expected. None of that is predictable yet from a biomarker or a body type.
If you're having this conversation with a prescriber, the mechanism chart matters less than your own history: what side effects you can actually live with, what your insurance will cover, and whether a compound that isn't approved yet is even on the table for you. Retatrutide specifically is only reachable as a research compound right now, not a prescription option for most people.
Understanding the mechanism is genuinely useful. Just don't let "more receptors" quietly become "automatically better for me." The research isn't there yet, and your own results are what will actually tell you.